Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis

References

• Martinelli I. Counseling women about hormonal therapy. Thromb Res 2009;123(Suppl. 2):574–8.
   Google Scholar
• Blanco-Molina A, Trujillo-Santos J, Tirado R, . Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost 2009;101:478–82.
   PubMed Web of Science ®Google Scholar
• Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328–36.
   PubMed Web of Science ®Google Scholar
• Dinger JC, Heinemann LAJ, Kül-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation. Contraception 2007;72: 344–54.
   Web of Science ®Google Scholar
• Vessey M, Painter R, Yeates D. Mortality in relation to oral contraceptive use and cigarette smoking. Lancet 2003;362:185–91.
   PubMed Web of Science ®Google Scholar
• Colditz GA. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses’ Health Study. Ann Intern Med 1994;120:821–6.
   PubMed Web of Science ®Google Scholar
• Beral V, Hermon C, Kay C, . Mortality associated with oral contraceptive use: 25 year follow-up cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study. BMJ 1999;318:96–100.
   PubMed Web of Science ®Google Scholar
• Hannaford PC, Iversen L, Macfarlane TV, . Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ 2010;340:c927. doi: 10.1136/bmj.c927.
   PubMed Web of Science ®Google Scholar
• Jick H, Kaye IA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third-generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321: 1190–5.
   PubMed Web of Science ®Google Scholar
• Farley TMM, Meirik O, Chang CL, . Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582–8.
   PubMed Web of Science ®Google Scholar
• Kemmeren IM, Algra A, Grobee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:1–7.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Cardiovascular disease and use of oral and injectable contraceptives. Contraception 1998;57:315–24.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use, 4th edn. Geneva: WHO 2008, RHRH/08.19.
   Google Scholar
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006;73:566–70.
   PubMed Web of Science ®Google Scholar
• Cole JA, Norman H, Doherthy M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007;109:339–46.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, . Meta-analysis of observational studies in epidemiology. A proposal for reporting. JAMA 2000;283:2008–12.
   PubMed Web of Science ®Google Scholar
• Jovell A, Navarro-Rubio MD. Evaluación de la evidencia científica. Med Clín 1995;105:740–3.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
   PubMed Web of Science ®Google Scholar
• Galbraith R. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889–94.
   PubMed Web of Science ®Google Scholar
• Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135:1301–9.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
   PubMed Web of Science ®Google Scholar
• Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, . Enhancement by factor V Leiden mutation of risk of deep venous thrombosis associated with oral contraceptives containing third-generation progestogen. Lancet 1995;346:1593–6.
   PubMed Web of Science ®Google Scholar
• Bloemenkamp KW, Rosendaal FR, Buller HR, . Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Int Med 1999;159:65–70.
   PubMed Web of Science ®Google Scholar
• Farmer RD, Lawrenson RA, Todd JC, . Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK MediPIus Database. Hum Reprod Update 1999;5:688–706
   PubMed Web of Science ®Google Scholar
• Farmer RD, Lawrenson RA, Todd IC, . A comparison of the risks of venous thromboembolism disease in association with different combined oral contraceptives. Br J Pharmacol 2000;49:580–90.
   Web of Science ®Google Scholar
• Jick H, Jick SS, Gwewich K, . Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589–93.
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2006;73:223–8.
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception 2007;76:4–7.
   PubMed Web of Science ®Google Scholar
• Lidegaard O. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study. Acta Obstet Gynecol Scand 1998;76:252–60.
   Web of Science ®Google Scholar
• Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five year national case-control study. Contraception 2002;65:187–96.
   PubMed Web of Science ®Google Scholar
• Parkin L, Skegg DC, Wilson M, . Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355: 2133–4.
   PubMed Web of Science ®Google Scholar
• Seaman HE, de Vries CS, Farmer RD. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2004;13:427–36.
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Lewis MA, Heinemann LA, . Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996;312:83–8.
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhost FM, Vandenbroucke JP, . The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339b2921 doi:10.1136/bmj.b2921.
   PubMed Web of Science ®Google Scholar
• Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001;358:1427–9.
   PubMed Web of Science ®Google Scholar
• Poulter NR, Chang CL, Farley TMM, . Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organisation Collaborative study of Cardiovascular Diseases and Steroid Hormone Contraception. Lancet 1995;346:1575–82.
   PubMed Web of Science ®Google Scholar
• Farmer RD, Lawrenson RA, Thompson CR, . Population based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83–8.
   PubMed Web of Science ®Google Scholar
• Hedenmalm K, Samuelsson E, Spigset O. Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential risk factors for fatal outcome. Acta Obstet Gynecol Scand 2004;83:576–85.
   PubMed Web of Science ®Google Scholar
• Herings RM, Urquhart J, Leufkens HG. Risk of venous thromboembolism among users of different oral contraceptives. Lancet 1999;354:127–8.
   PubMed Web of Science ®Google Scholar
• Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 340:d2151. doi:10.1136/bmj.d2151.
   Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339: b2890. doi: 10.1136/bmj.b2890.
   PubMed Web of Science ®Google Scholar
• Parkin L, Sharples K, Hernandez RK, Jick JS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;340:d2139. doi:10.1136/bmj.d2139.
   Web of Science ®Google Scholar
• Winkler UH. Haemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 2000;62:11S–20S.
   PubMed Web of Science ®Google Scholar
• Kemmeren JM, Algra A, Meijers JCM, . Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeyden mutation: a randomized trial. Blood 2004; 103:927–33.
   PubMed Web of Science ®Google Scholar
• Tans G, Van Hylckama Vlieg A, Thomassen MCLGD, . Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122: 465–70.
   PubMed Web of Science ®Google Scholar
• van Vliet H, Winkel TA, Noort I, . Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004;2:2060–2.
   PubMed Web of Science ®Google Scholar
• van Vliet H, Frolich M, Christella M, . Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005;20:563–8.
   PubMed Web of Science ®Google Scholar
• Pomp ER, Le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289–96.
   PubMed Web of Science ®Google Scholar
• The European Agency for the Evaluation of Medical Products. CPMP Public assessment report: Combined oral contraceptives and venous thromboembolism. Doc. Ref: EMEA/CPMP/2201/01/en/Final
   Google Scholar
• James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311–5.
   PubMed Web of Science ®Google Scholar
• Heinemann LA, Dinger JC, Assmann A, Minh TD. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation “pill scare”. Contraception 2010;81: 401–7.
   PubMed Web of Science ®Google Scholar
• Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003;326: 257.
   PubMed Web of Science ®Google Scholar
• Seeger JD, Loughlin J, Eng PM, . Risk of thromboembolism in women taking ethinylestradiol/ drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587–93.
   PubMed Web of Science ®Google Scholar
• Kluft C, Endrikat J, Mulder SM, . A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 2006;73:336–43.
   PubMed Web of Science ®Google Scholar
• Franks S, Layton A, Glasier A. Cyproterone acetate/ ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum Reprod 2008;23:231–2.
   PubMed Web of Science ®Google Scholar
• Committee on Safety of Medicines. Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE). Curr Prob Pharmacovigil 2002;28:9–10.
   Google Scholar
• Van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168–74.
   PubMed Web of Science ®Google Scholar
• Peeters, M. ClinicalTrials.gov. A study to evaluate the exposure of norelgestromin and ethinyl estradiol from commercial lots of EVRA® (a transdermal contraceptive patch manufactured by LOHMANN Therapie-Systeme) and CILEST® (an oral contraceptive). Study ID Number: CR002212. ClinicalTrials.gov Identifier: NCT00258063, Inform 4-3-2008.
   Google Scholar
• Johnson JV, Lowell J, Badger GJ, Rosing J. Effects of oral and transdermal hormonal contraception on vascular risk markers. Obstet Gynecol 2008;111:278–84.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Burke AE, Barnhart KT, . Effects of switching from oral to transdermal or vaginal contraception on markers of thrombosis. Contraception 2008;78: 451–8.
   PubMed Web of Science ®Google Scholar
• Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA® and levonorgestrel contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010;81: 16–21.
   PubMed Web of Science ®Google Scholar
• Rosing J, Middeldorp S, Curvers J, . Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999;354: 2036–40.
   PubMed Web of Science ®Google Scholar
• Tans G, Curvers J, Middeldorp S, . A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000;84:15–21.
   PubMed Web of Science ®Google Scholar
• The Oral Contraceptive and Haemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on haemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67: 173–85.
   PubMed Web of Science ®Google Scholar
• van Rooijen M, Silveira A, Hamsten A, Bremme K. Sex hormone-binding globulin – A surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004;190:332–7.
   PubMed Web of Science ®Google Scholar
• Heinemann LAJ, Kluft C, Spannagl M, Maat MPM. The association between extrinsic activated protein C resistance and venous thromboembolism in women. Contraception 2002;66:297–304.
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Shively CA, Morgan TM, . Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol 1990;75:217–22.
   PubMed Web of Science ®Google Scholar
• Bezemer I, van der Meer FJM, Eikenboom JCJ, . The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009;169:610–5.
   PubMed Web of Science ®Google Scholar
• Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006;73:166–78.
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8: 979–86.
   PubMed Web of Science ®Google Scholar
• Farley TM, Meirik O, Poulter NR, . Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1999;54:193–8.
   Google Scholar